Browse News
Filter News
Found 40 articles
-
It was a busy, busy week for clinical trial news and updates, largely driven by the annual ASCO meeting taking place June 3-7 in Chicago.
-
RhoVac AB announced Tuesday that its candidate therapeutic for prostate cancer failed to meet targets in a Phase IIb study.
-
RhoVac's phase IIb study in prostate cancer , BRaVac, failed to meet its primary endpoint
5/30/2022
RhoVac AB, a Swedish cancer immunotherapy company, regrets to announce on May 29th, 2022, that its phase IIb study in prostate cancer, BRaVac, in spite of the previous positive results related to the compound, failed to demonstrate RV001 superiority over placebo in preventing progression in patients with biochemical recurrence after curative intent therapy.
-
Pre-clinical findings support the potential use of RhoVac's drug candidate, onilcamotide, across several cancers
5/18/2022
RhoVac AB ("RHOVAC") today, 18th May 2022, announces preclinical findings from its collaboration with St. John's Research Institute (SJRI), a unit of CBCI Society for Medical Education, in Bangalore India.
-
RhoVac AB announces Database Lock in its clinical phase IIb trial of onilcamotide
5/10/2022
RhoVac AB ("RhoVac"), a Swedish cancer immunotherapy company, announces today on May 10th, 2022 , that its phase IIb study in prostate cancer, BRaVac, has reached "Database Lock".
-
The Canadian Intellectual Property Office intends to grant RhoVac's patent application for RV001 (onilcamotide) cancer vaccine
1/24/2022
RhoVac AB ("RhoVac") announces today, 24th January 2022, that the Canadian Intellectual Property Office ("CIPO") has issued a " Notice of Allowance", which means that it intends to grant RhoVac's patent application for RV001 (onilcamotide) cancer vaccine.
-
Another clean interim safety review of RhoVac's clinical phase IIb study in prostate cancer
12/9/2021
RhoVac AB, a Swedish cancer immunotherapy company, announces on December 9th, 2021, that its Data & Safety Monitoring Committee has conducted a planned interim safety review of its clinical phase IIb trial in prostate cancer, known as BRaVac.
-
Biopharma and life sciences companies from across the globe provide updates on their pipelines and business operations.
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
RhoVac presents 3-year follow-up results of the phase I/II study in prostate cancer
10/5/2021
RhoVac AB, a Swedish cancer immunotherapy company, announces on October 5, 2021, that it has received and validated the top line results from its 3-year follow-up of the patients who took part in its phase I/II study that was concluded in 2018.
-
Clinical Catch-Up: September 20-24
9/27/2021
There was still some carryover from the European Society of Medical Oncology Congress 2021, but there was plenty of other clinical trial news last week. Here’s a look. -
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
Clean interim safety review of RhoVac's clinical phase IIb study in prostate cancer
7/9/2021
RhoVac AB ("RhoVac"), a Swedish cancer immunotherapy company, announces today on July 9th 2021, that its Safety Monitoring Committee has conducted a planned interim safety review of its clinical phase IIb trial in prostate cancer, known as BRaVac.
-
Biopharma and life sciences companies from across the globe provide updates on their business operations and pipelines.
-
RhoVac Confirms Forecast - BRaVac Phase IIb study recruitment to close in Quarter 3 2021
5/31/2021
RhoVac AB, a Swedish cancer immunotherapy company, announces , May 31, 2021, that it confirms its previous forecast to be able to conclude recruitment for its multi-centre BRaVac Phase IIb study in Quarter 3 2021.
-
Biopharma and life sciences companies from around the globe provide updates on their businesses and pipelines.
-
Mount Sinai Hospital in New York joins RhoVac's Phase IIb Study in Prostate Cancer
4/21/2021
RhoVac AB, a Swedish cancer immunotherapy company, announces , April 21st 2021, that the prestigious Mount Sinai hospital in New York is initiated today as the latest addition to US trial centres in RhoVac's clinical phase IIb study, "BRaVac", in prostate cancer.
-
Global Covid-19 Vaccination Roll-out causes delay to RhoVac's Phase IIb study
3/8/2021
RhoVac AB ("RhoVac"), a Swedish cancer immunotherapy company, announces today, March 8th , 2021, that its clinical phase IIb study, "BRaVac", in prostate cancer, will be somewhat further delayed as Covid-19 vaccinations are rolled out to the study population.
-
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.